CANCER CELL BIOLOGY PROGRAM (Project-113) ABSTRACT Overview and Goals: Accumulation of defects in the regulation of cell behavior results in uncontrolled proliferation, immune evasion, invasiveness and metastasis. Understanding these mechanisms will provide new diagnostic markers and therapeutic targets. The major goal of the Cancer Cell Biology (CCB) Program is to foster and improve research focused on dissecting the cellular regulatory functions that establish and maintain this malignant phenotype and to apply this knowledge to translational and clinical investigations. CCB members have expertise in many areas and disciplines: Cell Cycle Regulation, Apoptosis and Autophagy, Developmental Biology and Stem Cells, Immunotherapy/Immunology, Signal Transduction and Tumor Microenvironment and Metastasis. This deep and diverse expertise results in collaborations, enhanced training and facilitation of technological innovations through UCCC Shared Resources (SR). Research Highlight: A multidisciplinary team including members at the UCB consortium site mapped the cell cycle phosphoproteome of the yeast centrosome. This molecular resource will provide foundational knowledge about the cell cycle in cancer and other diseases (Science, 20111). Program Activities: To accomplish its goal, the CCB program co-leaders employ resources provided by the UCCC to foster interactions by organizing retreats, mentoring programs, and weekly seminars attended by program members, students, fellows, and non-program faculty. Our collaborative publications and grants demonstrate the success of our endeavors. Furthermore, key members of the CCB Program have collaborated effectively with other programs, resulting in joint grant awards and submissions. Members: The program has 43 Full members with $2.2M in grant funding from NCI and $5.9M in other peer-reviewed research grant funding in 2015. Members are from 5 basic science (21%) and 7 clinical (51%) departments in the SOM, from the School of Dental Medicine (5%), and the School of Public Health (1%) at AMC; and the College of Liberal Arts and Sciences (2%) at the downtown campus. Thirteen percent of members are at UCB; 2% at CSU; and 5% are at non-consortium institutions. Program members published 690 cancer-relevant publications in the previous grant period of which 41% were inter- and 17% were intra-programmatic. Future Directions: We will enhance our high degree of productivity and collaborative science by continuing to support fundamental research in cell biology, by guiding these fundamental discoveries into the clinic and by leveraging the scientific strengths found in the consortium institutions unique to the State of Colorado. Specifically, we will accomplish this goal by enhancing the training and mentoring of students, fellows and junior faculty, by increasing the number of novel cancer biology and mechanism discoveries that lead to collaborative scientific studies and are translated into clinical applications, and by providing access to new technologies and innovative experimental models of cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee A - Cancer Centers (NCI-A)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Colorado Denver
Domestic Higher Education
United States
Zip Code
Kogut, Igor; McCarthy, Sandra M; Pavlova, Maryna et al. (2018) High-efficiency RNA-based reprogramming of human primary fibroblasts. Nat Commun 9:745
Collins, Keagan P; Jackson, Kristen M; Gustafson, Daniel L (2018) Hydroxychloroquine: A Physiologically-Based Pharmacokinetic Model in the Context of Cancer-Related Autophagy Modulation. J Pharmacol Exp Ther 365:447-459
Villalobos, Victor Manuel; Hall, Francis; Jimeno, Antonio et al. (2018) Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor. Ann Surg Oncol 25:768-775
Montford, John R; Lehman, Allison M B; Bauer, Colin D et al. (2018) Bone marrow-derived cPLA2? contributes to renal fibrosis progression. J Lipid Res 59:380-390
Kiseljak-Vassiliades, Katja; Zhang, Yu; Bagby, Stacey M et al. (2018) Development of new preclinical models to advance adrenocortical carcinoma research. Endocr Relat Cancer 25:437-451
Nellan, Anandani; Rota, Christopher; Majzner, Robbie et al. (2018) Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells. J Immunother Cancer 6:30
Goodspeed, Andrew; Jean, Annie; Costello, James C (2018) A Whole-genome CRISPR Screen Identifies a Role of MSH2 in Cisplatin-mediated Cell Death in Muscle-invasive Bladder Cancer. Eur Urol :
Niemeyer, Brian F; Oko, Lauren M; Medina, Eva M et al. (2018) Host Tumor Suppressor p18INK4c Functions as a Potent Cell-Intrinsic Inhibitor of Murine Gammaherpesvirus 68 Reactivation and Pathogenesis. J Virol 92:
Witt, Davis A; Donson, Andrew M; Amani, Vladimir et al. (2018) Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy. Pediatr Blood Cancer 65:e26960
McCoach, Caroline E; Le, Anh T; Gowan, Katherine et al. (2018) Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer. Clin Cancer Res 24:3334-3347

Showing the most recent 10 out of 1634 publications